2024 A Focus on Cellular Therapies, T Cell Engagers and TIL Therapies


tuesday, april 16, 2024 |1-5 P.M. ET
live via zoom webinar

Register Now

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of cellular therapies, T cell engagers and TIL Therapies. FREE for healthcare professionals, students, patients and patient advocates.

New for 2024

  • Session on TIL therapy 
  • Cancer Immunotherapy in Practice will include practical aspects of TIL therapy & obstacles faced by institutions during the clinical trials
The 2024 Advances in Cancer Immunotherapy™ series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc.  (MSD), and Novartis Pharmaceuticals Corporation (supporters as of March 22, 2024).

Program Organizers

Christian Capitini, MD
University of Wisconsin-Madison

Pawel Muranski, MD
Columbia University
Medical Center

Shari A. Pilon-Thomas, PhD  Moffitt Cancer Center

Program Snapshot

Credits Available
Physician Education: 3.75 AMA PRA Category 1TM
Pharmacy Education: 3.75 contact hours (0.375 CEUs)
Nursing Education: 3.75 contact hours

Program Date & Location

Tuesday, April 16, 2024 at 1-5 p.m. ET
Live via Zoom Webinar

Program Cost

FREE for healthcare professionals, students, patients and patient advocates.

Register for A Focus on Cellular Therapies, T Cell Engagers & TIL Therapies >

Program Agenda

1–1:10 p.m.


Welcome and Introduction

1:101:30 p.m.

  CAR for Hematologic Malignancies: CD19 
Michael Jain, MD, PhD – Moffitt Cancer Center

1:301:50 p.m.


CAR for Hematologic Malignancies: BCMA 
Marco Davila, MD, PhD – Roswell Park Comprehensive Cancer Center

1:502:20 p.m.


Amod Sarnaik, MD – Moffitt Cancer Center

2:202:50 p.m.


Ecaterina Dumbrava, MD – The University of Texas MD Anderson Cancer Center

2:50–3:20 p.m.


T cell Engagers
Rajshekhar Chakraborty, MD – Columbia University Herbert Irving Comprehensive Cancer Center

3:203:35 p.m.



3:35–4:15 p.m


Cancer Immunotherapy in Practice

  • Bonnie Yates, MSN, CPNP-AC – National Institutes of Health (CAR toxicities) 
  • Marian Dam, DNP, APRN, CDCES – Moffitt Cancer Center (Coordinating aspects of TIL therapy; protocol-based obstacles)

4:15–5 p.m


Faculty Panel

    SITC ACI Series

    This program is part of the SITC ACI series. View below to explore more programs in the 2024 ACI series.

    Program Details

    Target Audience

    The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

    Case Study Submission Information

    As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to education@sitcancer.org.

    Program Learning Objectives

    • Describe the mechanisms of cell therapies, T cell engagers and TIL therapies.
    • Summarize recent updates in the use of cell therapies, T cell engagers and TIL therapies clinically.
    • Outline common toxicities with cell therapies, T cell engagers and TIL therapies and their management.
    • Identify unique institutional resources required for the appropriate use of cell therapies.

    Accreditation Information

    Joint Accreditation Statement

    thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

    ABIM_Logo.jpgSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Physician Continuing Medical Education

    PACE designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Continuing Pharmacy Education

    PACE designates this continuing education activity for 3.75 contact hour(s) (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

    Continuing Nursing Education

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.75 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

    Disclosures and ADA Info

    Disclosure of Conflicts of Interest

    PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

    Avoid Fraudulent ACI Websites

    Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

    All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org. If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.